Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $49.00 at HC Wainwright

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price objective boosted by HC Wainwright from $47.00 to $49.00 in a research note issued to investors on Tuesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other research analysts also recently commented on SNDX. Barclays lifted their price objective on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a research report on Thursday, August 15th. Stifel Nicolaus lifted their price objective on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research report on Monday, October 14th. JPMorgan Chase & Co. decreased their price objective on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Bank of America lifted their price objective on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. Finally, UBS Group started coverage on shares of Syndax Pharmaceuticals in a report on Thursday, October 24th. They set a “buy” rating and a $37.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, Syndax Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.00.

Syndax Pharmaceuticals Stock Up 1.0 %

Syndax Pharmaceuticals stock opened at $16.79 on Tuesday. Syndax Pharmaceuticals has a 1-year low of $14.50 and a 1-year high of $25.34. The company has a fifty day simple moving average of $18.99 and a 200 day simple moving average of $20.27.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same period last year, the business earned ($0.73) EPS. On average, equities analysts expect that Syndax Pharmaceuticals will post -3.61 earnings per share for the current fiscal year.

Institutional Trading of Syndax Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of SNDX. Northwestern Mutual Wealth Management Co. acquired a new stake in Syndax Pharmaceuticals in the 2nd quarter worth about $27,000. Values First Advisors Inc. acquired a new stake in Syndax Pharmaceuticals in the 3rd quarter worth about $30,000. nVerses Capital LLC acquired a new stake in Syndax Pharmaceuticals in the 2nd quarter worth about $33,000. Quantbot Technologies LP acquired a new position in shares of Syndax Pharmaceuticals in the 3rd quarter valued at approximately $49,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after buying an additional 541 shares in the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).